You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾(6185.HK)漲超7% 馬來西亞批准其新冠疫苗作為加強針
格隆匯1月7日丨康希諾(6185.HK)漲超7%,報161.5港元,總市值400億港元。馬來西亞衞生部總監努爾·希沙姆昨日宣佈,有條件批准中國康希諾疫苗作為加強針供18歲以上民眾接種。努爾説,康希諾疫苗作為加強針將提供給接種第一針康希諾疫苗3到6個月後的民眾接種。馬衞生部門此前已有條件批准科興疫苗作為加強針。馬來西亞是今年6月批准康希諾疫苗有條件註冊。從今年8月起,康希諾疫苗開始運抵馬來西亞,並以其單劑疫苗的特性被廣泛應用於該國偏遠地區。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account